[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR063601A1 - Arilamidas sustituidas por tiazol u oxazol - Google Patents

Arilamidas sustituidas por tiazol u oxazol

Info

Publication number
AR063601A1
AR063601A1 ARP070104958A ARP070104958A AR063601A1 AR 063601 A1 AR063601 A1 AR 063601A1 AR P070104958 A ARP070104958 A AR P070104958A AR P070104958 A ARP070104958 A AR P070104958A AR 063601 A1 AR063601 A1 AR 063601A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
optionally substituted
heteroaryl
hydrogen
Prior art date
Application number
ARP070104958A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR063601A1 publication Critical patent/AR063601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se proporcionan también métodos para utilizar los compuestos en el tratamiento de enfermedades, en ellas los compuestos actúan como antagonistas de receptores P2X3 y/o P2X2/3 y métodos para la obtención de los compuestos de interés. Reivindicación 1: Un compuesto de la fórmula 1, o sales farmacéuticamente aceptables del mismo, en la que: R1 es un grupo de la fórmula A o fórmula B; en las que: X es -S- u -O-; y Ra y Rb con independencia entre sí son hidrógeno; alquilo C1-6, alcoxi C1-6, alquil C1-6-sulfonil-alquilo C1-6, halo-alquilo C1-6, halo-alcoxi C1-6, hetero-alquilo C1-6, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-6, aminocarbonilo; alcoxi C1-6carbonilo; o ciano; o Ra y Rb junto con el átomo, al que están unidos, pueden formar un grupo fenilo, que está opcionalmente sustituido, R2 es fenilo opcionalmente sustituido; piridinilo opcionalmente sustituido; pirimidinilo opcionalmente sustituido; piridazinilo opcionalmente sustituido; o tiofenilo opcionalmente sustituido; R3 es hidrógeno; alquilo C1-6, hetero-alquilo C1-6 o ciano; R4 es hidrógeno; alquilo C1-6 o hetero-alquilo C1-6; o R3 y R4 junto con el átomo al que están unidos pueden formar un anillo carbocíclico C3-6, R5 es alquilo C1-6, hetero- alquilo C1-6, halo-alquilo C1-6, N-(alquil C1-6)amino; N,N-di-(alquil C1-6)-amino; cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6, aril-alquilo C1-6, heteroaril-alquilo C1-6, heterociclil-alquilo C1-6, heterocicliloxi; ariloxi-alquilo C1-6, -(CRcRd)rn-C(O)-R8 en el que: m es 0 o 1; Rc y Rd con independencia entre sí son hidrógeno; o alquilo C1-6, y R8 es hidrógeno; alquilo C1-6 hetero-alquilo C1-6 cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6; aril-alquilo C1-6; heteroaril-alquilo C1-6; heterociclil-alquilo C1-6; cicloalquiloxi C3-7; ariloxi; heteroariloxi; heterocicliloxi; cicloalquiloxi C3-7-alquilo C1-6; ariloxi-alquilo C1-6; heteroariloxi- alquilo C1-6, heterocicliloxi-alquilo C1-6; o -NR9R10, en el que; R9 es hidrógeno; o alquilo C1-6 y R10 es hidrógeno; alquilo C1-6, hetero-alquilo C1-6; cicloalquilo C3-7; arilo; heteroarilo; heterociclilo; cicloalquil C3-7-alquilo C1-6, aril- alquilo C1-6, heteroaril-alquilo C1-6 o heterociclil-alquilo C1-6, o R4 y R5 junto con el átomo al que están unidos forman un anillo carbocíclico C3-6, que está opcionalmente sustituido por hidroxi; o R4 y R5 junto con el átomo al que están unidos forman un anillo heterocíclico C4-6 que contienen uno o dos heteroátomos elegidos con independencia entre sí entre O, N y S; o R3, R4 y R5 junto con el átomo al que están unidos forman un heteroarilo de seis eslabones que tiene uno dos átomos de N y que está opcionalmente sustituido por halógeno, amino o alquilo C1-6; R6 es alq1uilo C1-6, alquiloxi C1-6; halógeno; haloalquilo C1-6, halo-alcoxi C1-6, o ciano.
ARP070104958A 2006-11-09 2007-11-07 Arilamidas sustituidas por tiazol u oxazol AR063601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85828306P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
AR063601A1 true AR063601A1 (es) 2009-02-04

Family

ID=39149180

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104958A AR063601A1 (es) 2006-11-09 2007-11-07 Arilamidas sustituidas por tiazol u oxazol

Country Status (17)

Country Link
US (1) US7786110B2 (es)
EP (1) EP2091927B1 (es)
JP (1) JP5084839B2 (es)
KR (2) KR101152714B1 (es)
CN (1) CN101528717B (es)
AR (1) AR063601A1 (es)
AT (1) ATE517097T1 (es)
AU (1) AU2007316681B2 (es)
BR (1) BRPI0718714B8 (es)
CA (1) CA2668399C (es)
CL (1) CL2007003192A1 (es)
ES (1) ES2367455T3 (es)
IL (1) IL198301A (es)
MX (1) MX2009004900A (es)
PE (1) PE20081475A1 (es)
TW (1) TW200829584A (es)
WO (1) WO2008055840A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528717B (zh) 2006-11-09 2013-04-24 弗·哈夫曼-拉罗切有限公司 噻唑和*唑-取代的芳基酰胺类化合物
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
CA2703909A1 (en) * 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
AU2008319309B2 (en) * 2007-10-31 2012-09-06 Merck Sharp & Dohme Llc P2X3 receptor antagonists for treatment of pain
DK2234976T3 (da) * 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
KR101284510B1 (ko) * 2007-12-17 2013-07-23 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도
ES2570628T3 (es) * 2007-12-17 2016-05-19 Hoffmann La Roche Nuevas arilamidas con sustitución imidazol
ES2517602T3 (es) * 2007-12-17 2014-11-03 F. Hoffmann-La Roche Ag Derivados arilamida sustituidos con tetrazol y su utilización como antagonistas de receptores purinérgicos P2X3 y/o P2X2/3
CA2715835C (en) * 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
EP2346825A2 (en) 2008-09-18 2011-07-27 Evotec AG Modulators of p2x3 receptor activity
KR101347958B1 (ko) * 2008-12-16 2014-02-14 에프. 호프만-라 로슈 아게 티아디아졸-치환된 아릴아미드
CN102438989B (zh) * 2009-06-22 2015-05-27 霍夫曼-拉罗奇有限公司 噁唑酮和吡咯烷酮取代的芳基酰胺
CN102574778B (zh) 2009-06-22 2015-01-07 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
CN103096893B (zh) * 2010-06-04 2016-05-04 阿尔巴尼分子研究公司 甘氨酸转运体-1抑制剂、其制备方法及其用途
US9732048B2 (en) * 2012-12-07 2017-08-15 Bayer Cropscience Ag N-(isoxazol-3-yl)-aryl-carboxylic acid amides and use thereof as herbicides
EP2905282A1 (en) * 2014-02-05 2015-08-12 AXXAM S.p.A. Substituted thiazole or oxazole as P2X7 receptor antagonists
US10183937B2 (en) 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
RS63014B1 (sr) 2014-12-09 2022-04-29 Bayer Ag 1,3-tiazol-2-il supstituisani benzamidi
KR20160138877A (ko) 2015-05-26 2016-12-06 (주)펠리테크 마이크로파를 이용한 세라믹 발열 하이브리드 건조기
MA46229B1 (fr) 2016-09-15 2020-10-28 Boehringer Ingelheim Int Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
WO2020002090A1 (de) 2018-06-25 2020-01-02 Bayer Aktiengesellschaft Substituierte thiazolylpyrrolone sowie deren salze und ihre verwendung als herbizide wirkstoffe
EP3757103A1 (en) * 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN115884970A (zh) * 2020-09-24 2023-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277873B1 (en) 1999-03-25 2001-08-21 Dingwei Tim Yu Oxadiazole antifungal agents
EP1194421B1 (en) 1999-06-30 2005-10-12 H. Lundbeck A/S Selective npy (y5) antagonists
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7176242B2 (en) * 2001-11-08 2007-02-13 Elan Pharmaceuticals, Inc. N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2003105770A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
RS113904A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’－核苷前药
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004084890A1 (en) 2003-03-26 2004-10-07 Crc For Asthma Limited Therapeutic and prophylactic compositions and uses therefor
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
DE602004005033T2 (de) * 2003-05-12 2007-08-09 Pfizer Products Inc., Groton Benzamidinhibitoren des p2x7-rezeptors
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
PT1658302E (pt) 2003-07-25 2010-10-25 Centre Nat Rech Scient Análogos do nucleósido purina para o tratamento de doenças provocadas por flaviviridae incluindo hepatite c
PL1725540T3 (pl) * 2004-03-05 2013-02-28 Hoffmann La Roche Diaminopirymidyny jako antagoniści p2x3 i p2x2/3
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
CN103159692B (zh) 2006-06-29 2015-03-18 弗·哈夫曼-拉罗切有限公司 四唑取代的芳基酰胺类
CN101528717B (zh) 2006-11-09 2013-04-24 弗·哈夫曼-拉罗切有限公司 噻唑和*唑-取代的芳基酰胺类化合物
CA2703909A1 (en) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
IL198301A0 (en) 2010-02-17
WO2008055840A1 (en) 2008-05-15
JP5084839B2 (ja) 2012-11-28
US7786110B2 (en) 2010-08-31
PE20081475A1 (es) 2008-10-18
CA2668399A1 (en) 2008-05-15
CL2007003192A1 (es) 2008-06-20
BRPI0718714B8 (pt) 2021-05-25
US20080132494A1 (en) 2008-06-05
MX2009004900A (es) 2009-05-19
CN101528717B (zh) 2013-04-24
TW200829584A (en) 2008-07-16
KR101165936B1 (ko) 2012-07-19
BRPI0718714A2 (pt) 2013-11-26
KR20090086073A (ko) 2009-08-10
BRPI0718714B1 (pt) 2020-09-29
CA2668399C (en) 2015-01-27
AU2007316681A1 (en) 2008-05-15
JP2010509264A (ja) 2010-03-25
AU2007316681B2 (en) 2013-01-24
CN101528717A (zh) 2009-09-09
EP2091927B1 (en) 2011-07-20
KR20120034766A (ko) 2012-04-12
EP2091927A1 (en) 2009-08-26
IL198301A (en) 2013-06-27
KR101152714B1 (ko) 2012-06-18
ES2367455T3 (es) 2011-11-03
ATE517097T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
AR063601A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR061667A1 (es) Arilamidas sustituidas con tetrazol
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
ES2515194T3 (es) Derivados de pirrolidina
ES2543567T3 (es) Métodos de utilización de inhibidores de ALK
AR073136A1 (es) Compuestos de pirrol
AR046394A1 (es) Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR061844A1 (es) Pirimidil-ciclopentanos como inhibidores de protein-quinasa akt
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR078463A1 (es) Composicion y metodo para controlar plagas de artropodos
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR054529A1 (es) Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6
AR041260A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.

Legal Events

Date Code Title Description
FB Suspension of granting procedure